June 28, 2024
Axcelead, Inc.

Notice of Change of Directors and Executive Officers

Axcelead, Inc. announces that the following executive appointments were made at theAnnual General Meeting of Shareholders held on June 28, 2024 and the Board of Directors
meeting held after the Annual General Meeting of Shareholders.
1. Directors (Effective June 28, 2024)
Name

New /New Position, etc.

Reappointment
Tomoyuki Fujisawa

Reappointment

Nobuhiro Todokoro

New

Chairperson
Representative Director

Yoshinori Ikeura

Reappointment

Board Director

Satoru Iino

Reappointment

Board Director

New

Board Director

Junichi Kajimoto
Seiji Toyama

Reappointment

External Board Director

Tadashi Takiguchi

Reappointment

External Board Director

Nobuhiko Yamada

Reappointment *1Director (Full-time Audit Board Member)

Takuji Ikuta

Reappointment

Outside Director (Audit Committee Member)Emi Kunitomo

Reappointment

Outside Director (Audit Committee Member)*1 Nobuhiko Yamada, who was a Board Director, was reappointed as a member of the AuditCommittee. Nobuhiko Yamada will be a full-time Audit Board Member.
*2

Hiroki Maekawa, Masamichi Sato, and Miho Fujisawa, who were directors, will retire
from their posts as directors at the end of the Ordinary General Meeting of Shareholders
on June 28, 2024 due to expiration of their terms of office, and will become executiveofficers. This is based on the Group's policy to further strengthen corporate governanceby separating management oversight and execution.

*3 Atsushi Matsumura, the former Chairperson, and Makoto Kojima, Director, who was amember of the Audit Committee, resigned due to expiration of their term of office at theend of the Ordinary General Meeting of Shareholders on June 28, 2024.

[Reason for the change in representative directors]
To further strengthen the management structure in accelerating the Group's growth.
2. Executive Officer (effective July 1, 2024)
Name

New Position

former position

Nobuhiro Todokoro

Representative Director,

Corporate Officer

President and CEO
Yoshinori Ikeura

Borad Director, Co-CEO andPresident and CEOCTO
Board Director and Chief
Hiroki Maekawa

Corporate Officer CFO

Financial Officer / Chief
Administrative Officer(CFO/CAO)

Masamichi Sato
Miho Fujisawa
Yo Nakajima
Satoshi Takamatsu

Corporate Officer CSO
Corporate Officer (ImpactManagement Supervisor)
Corporate Officer (Group DXSupervisor)

Operating Officer（COO)
Corporate Officer Group HR
Corporate Officer, Group DX

Corporate Officer (CDMO

Corporate Officer, Head ofbusiness Supervisor)

CDMO BusinessCorporate Officer (DrugKengo Okada

Board Director and Chief

Discovery Support BusinessSupervisor)

Corporate Officer, Head ofCRO Business※CTO：Chief Technology Officer、CFO：Chief Financial Officer、CSO：Chief Strategic Officer

3. Profile of Nobuhiro Todokoro, new Representative Director, President and CEO
2023

Managing Director, Whiz Partners Inc. Resigned in conjunction with his
appointment as President and CEO of Axcelead, Inc.

2022

Representative Director, Senior Managing Executive Officer, Nitto DenkoCorporation

2021

Director, Senior Managing Executive Officer, Nitto Denko Corporation

2019

Director, Managing Executive Officer, Nitto Denko Corporation

2017

Executive Officer, General Manager of Information Functional Materials BusinessDivision, Nitto Denko Corporation
Director, Senior Executive Officer, General Manager of Information Functional
Materials Business Division, Nitto Denko Corporation

2015

Executive Officer, General Manager of Information Functional Materials Division,Information Functional Materials Business Unit, Nitto Denko Corporation

1989

Nitto Denko Corporation【About Axcelead】
Axcelead represents a holding company as healthcare platformer which owns a group ofcompanies which are developing a world-class healthcare platform for drug discovery.
Axcelead DDP, Japan’s first integrated drug discovery CRO, functions as the core companyof the Axcelead group that took over Takeda Pharmaceutical Company Limited's drug
discovery platform business in 2017. ARCALIS has become Japan's only one-stop mRNA
contract drug development and manufacturing organization (CDMO).
Axcelead also owns A-Digital which develops a drug discovery digital platform to increase
drug discovery efficacy by 100 times, and the American company, PassPort Technologies, Inc.
in San Diego, California (“PassPort”). PassPort is a company that develops combination
products of active pharmaceutical ingredients and medical devices based on next-generationtransdermal drug delivery technology. Axcelead will promote the drug discovery ecosystem inJapan and will make various contributions to healthcare broadly and globally.
For

more

informationon

https://www.axcelead-hd.com

Axcelead,pleasevisit

thecompany’swebsite

at